Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Lymphoma » Lymphoma, Non-Hodgkin » Lymphoma, T-Cell » Lymphoma, T-Cell, Cutaneous
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders » Lymphoma » Lymphoma, Non-Hodgkin » Lymphoma, T-Cell » Lymphoma, T-Cell, Cutaneous
Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders » Lymphoma » Lymphoma, Non-Hodgkin » Lymphoma, T-Cell » Lymphoma, T-Cell, Cutaneous
Description
A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders. MeSH
Hierarchy View
Subtype Terms (4)
Lymphoma, Primary Cutaneous Anaplastic Large Cell
151 drugs (107 approved, 44 experimental)
Lymphomatoid Papulosis
7 drugs (6 approved, 1 experimental)
Mycosis Fungoides
86 drugs (61 approved, 25 experimental)
Sezary Syndrome
124 drugs (81 approved, 43 experimental)
Approved Indicated Drugs (5)
Phase 4 Indicated Drugs (2)
Phase 3 Indicated Drugs (4)
Phase 2 Indicated Drugs (30)
Phase 1 Indicated Drugs (22)
Organization Involved with Phase 4 Indications (17)
Organization Involved with Phase 3 Indications (6)
Organization Involved with Phase 2 Indications (98)
Cancer and Leukemia Group B (CALGB)
Chinese Academy of Medical Sciences
City of Hope National Medical Center
Cyclacel Pharmaceuticals, Inc.
Eastern Cooperative Oncology Group
European Organisation for Research and Treatment of Cancer
Florida Academic Dermatology Centers
James Graham Brown Cancer Center
Johannes Wesling Klinikum, Minden, Germany
Karl Landsteiner Private University of Health Sciences
Koordinierungszentren für Klinische Studien bzw. Zentren für klinische Studien
Ludwig Institute for Cancer Research
Norwegian University of Science and Technology
Rochester Skin Lymphoma Medical Group, PLLC
Shijiazhuang Pharma Group (CSPC)
State University of New York, Buffalo
The Christie NHS Foundation Trust
Organization Involved with Phase 1 Indications (30)
Organization Involved with Other Experimental Indications (2)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.